News headlines about Pain Therapeutics (NASDAQ:PTIE) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.2721258599466 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Pain Therapeutics (NASDAQ:PTIE) traded up $0.08 during midday trading on Monday, hitting $3.97. The stock had a trading volume of 65,100 shares, compared to its average volume of 180,293. Pain Therapeutics has a 12 month low of $3.10 and a 12 month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter. research analysts predict that Pain Therapeutics will post -2.2 earnings per share for the current fiscal year.

Separately, Zacks Investment Research cut Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Pain Therapeutics (PTIE) Stock Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-pain-therapeutics-ptie-stock-price.html.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Stock Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related stocks with our FREE daily email newsletter.